Zhu Feng, Zhou Zihua, Liao Yuhua
Union Hospital, Huazhong University of Science and Technology, Tongji Medical College, Institute of Cardiology, Wuhan 430022, China.
Curr Opin Investig Drugs. 2008 Mar;9(3):286-94.
With increased understanding of the pharmacology of the renin-angiotensin system (RAS), many researchers have explored immunological approaches to inhibit components of the RAS for the treatment of hypertension. Active and passive immunizations of the various components of the RAS have been performed, utilizing renin, angiotensin I, angiotensin II and angiotensin II receptor type 1 vaccines. This review discusses the RAS as a target for the development of a hypertension vaccine, and evaluates the safety and efficacy of these vaccines.
随着对肾素-血管紧张素系统(RAS)药理学的深入了解,许多研究人员探索了通过免疫方法抑制RAS的组分来治疗高血压。已经利用肾素、血管紧张素I、血管紧张素II和1型血管紧张素II受体疫苗对RAS的各种组分进行了主动和被动免疫。本综述讨论了将RAS作为高血压疫苗开发的靶点,并评估了这些疫苗的安全性和有效性。